Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 25, Issue 3, 2011, Pages 251-258

  McLean, Rhondalyn C ^a,d   Hirsch, Glenn A ^a,b   Becker, Lewis C ^a   Kasch Semenza, Laura ^c   Gerstenblith, Gary ^a   Schulman, Steven P ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Beta Blocker theraphy; Beta Receptor Polymorphism; Ventricular Remodeling

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR;

ACUTE HEART INFARCTION; ADULT; AMINO ACID SEQUENCE; ARTICLE; BETA 1 ADRENERGIC RECEPTOR GENE; BETA 2 ADRENERGIC RECEPTOR GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE REMODELING; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79958253995     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6307-7     Document Type: Article

References (35)

1. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail. 2002;8:S465-71.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
3. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
4. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807-16.
5. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8. (Pubitemid 32479962)
6. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/ New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349:375-380.
7. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431-8.
8. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-49. (Pubitemid 36159890)
9. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V, et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med. 2004;117:451-8. (Pubitemid 39349582)
10. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33:9414-9. (Pubitemid 24272896)
11. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526-33. (Pubitemid 41362690)
12. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274:12670-4.
13. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300-5. (Pubitemid 37279854)
14. SotoodehniaN, Siscovick DS, Vatta M, Psaty BM, Tracy RP, Towbin JA, et al. Heckbert SR Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006;113:1842-8. (Pubitemid 43739395)
15. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, Tiret L, et al. Characterization of a unique genetic variant in the beta1- adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol. 1999;31:1025-32. (Pubitemid 29241538)
16. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. Jama. 2006;295:58-64.
17. Mark DB, Nelson CL, Califf RM, Harrell Jr FE, Lee KL, Jones RH, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation. 1994;89:2015-25.
18. Links JM, Becker LC, Shindledecker JG, Guzman P, Burow RD, Nickoloff EL, et al.Measurement of absolute left ventricular volume from gated blood pool studies. Circulation. 1982;65:82-91. (Pubitemid 12250894)
19. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-89. (Pubitemid 32289743)
20. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
21. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309. (Pubitemid 17178124)
22. Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, et al. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/ calmodulin kinase II. J Clin Invest. 2003;111:617-25. (Pubitemid 36278580)
23. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-30.
24. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation. 2004;110:1083-90. (Pubitemid 39319006)
25. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, et al. Subtype-specific alpha1- and beta-adrenoceptor signaling in the heart. Trends Pharmacol Sci. 2006;27:330-7. (Pubitemid 43850004)
26. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003;13:379-82. (Pubitemid 36900732)
27. Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS, et al. Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation. 2003;107:2021-4. (Pubitemid 36506077)
28. Barbato E, Berger A, Delrue L, Van Durme F, Manoharan G, Boussy T, et al. GLU-27 variant of beta2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease. Atherosclerosis. 2007;194:e80-6.
29. Eaton LW, Bulkley BH. Expansion of acute myocardial infarction: its relationship to infarct morphology in a canine model. Circ Res. 1981;49:80-8. (Pubitemid 11093182)
30. Korup E, Dalsgaard D, Nyvad O, Jensen TM, Toft E, Berning J. Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction. Am J Cardiol. 1997;80:449-53. (Pubitemid 27371749)
31. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288-93.
32. Akhter SA, D'Souza KM, Petrashevskaya NN, Mialet-Perez J, Liggett SB. Myocardial beta1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol. 2006;290:H1427-32.
33. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005;77:127-37. (Pubitemid 40269128)
34. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52:644-51.
35. Metra M, Covolo L, Pezzali N, Zaca V, Bugatti S, Lombardi C, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010;24:49-60.